Lee Rauch, miRagen
October 28, 2020 10:55 AM EDT
Financing

A small buy­out deal gives a pen­ny-stock biotech a boost and a sec­ond chance

Nicole DeFeudis

Editor

Just over a month af­ter for­mer mi­Ra­gen Ther­a­peu­tics COO Lee Rauch stepped up to take the helm, the mi­cro­cap is scoop­ing up Virid­i­an Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Four biotechs emerge with $800M and in-li­censed as­sets on Fri­day

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

A service from the Financial Times